{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:13:25Z","timestamp":1783358005307,"version":"3.54.6"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Primary diffuse large B cell lymphoma of the central nervous system (CNS DLBCL) is a rare malignancy with a distinct genetic profile. The clinicopathological significance of the mutation patterns remains unknown. Forty cases of primary CNS DLBCL were subjected to targeted exome sequencing covering 413 genes, including <jats:italic>MYD88<\/jats:italic>, <jats:italic>CD79B<\/jats:italic> and <jats:italic>PIM1<\/jats:italic>. Mutational analysis recognized two groups. The CDP (including <jats:italic>CD79B<\/jats:italic> and\/or <jats:italic>PIM1<\/jats:italic>mutations) group was identified in 27 cases (67.5%), and the non-CDP (without <jats:italic>CD79B<\/jats:italic> and PIM1 mutations) group was identified in 13 cases 32.5%). The CDP group tended to occur in older patients (median age 57.0 vs. 48.4 years, <jats:italic>p<\/jats:italic>=0.015). Patients in the CDP group had a significantly longer 2-year overall survival (OS) (76% and 40%, <jats:italic>p<\/jats:italic>=0.0372) than those in the non-CDP group. Multivariate analysis revealed that age less than 60 years, no MYC and BCL2 double expression, and CDP group were three independent risk factors indicating favorable OS. PyClone analysis revealed the subcloning heterogeneity between the groups. In addition, transcriptional sequencing was successfully performed in 8 cases. A total of 131 genes were significantly differentially expressed between these two groups. The major categories of biological processes that were significantly altered between these two groups related to intracellular metabolism mechanisms. We developed a new molecular classification to divide CNS DLBCL into CDP and non-CDP groups based on <jats:italic>CD79B<\/jats:italic> and <jats:italic>PIM1<\/jats:italic> mutational status. Patients with <jats:italic>PIM1<\/jats:italic> and\/or <jats:italic>CD79B<\/jats:italic> mutations had favorable long-term survival after high-dose methotrexate-based polychemotherapy.<\/jats:p>","DOI":"10.3389\/fonc.2022.824632","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T07:59:23Z","timestamp":1644393563000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS"],"prefix":"10.3389","volume":"12","author":[{"given":"Jihao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.anndiagpath.2018.09.014","article-title":"Aggressive B Cell Lymphomas in the 2017 Revised WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","volume":"38","author":"Grimm","year":"2019","journal-title":"Ann Diagn Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1677157","article-title":"Have Treatment Protocols for Primary CNS Lymphoma Advanced in the Past 10 Years","volume":"19","author":"Seidel","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/35000501","article-title":"Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma With Therapeutic Implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated With Distinct Pathogenic Mechanisms and Outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000759","article-title":"Molecular Profiling of Primary Central Nervous System Lymphomas - Predictive and Prognostic Value","volume":"32","author":"Ho","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"56342","DOI":"10.3791\/56342","article-title":"Detection of Rare Mutations in CtDNA Using Next Generation Sequencing","author":"Lv","year":"2017","journal-title":"J Visualized Experiments JoVE"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1754","article-title":"Integrative Genomics Viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2883","article-title":"PyClone: Statistical Inference of Clonal Population Structure in Cancer","volume":"11","author":"Roth","year":"2014","journal-title":"Nat Methods"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2:PO.17.00091.","DOI":"10.1200\/PO.17.00091","article-title":"Accurate RNA Sequencing From Formalin-Fixed Cancer Tissue To Represent High-Quality Transcriptome From Frozen Tissue","volume":"2018","author":"Li","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","article-title":"ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis","volume":"37","author":"Liu","year":"2020","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-Based Genome Alignment and Genotyping With HISAT2 and HISAT-Genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt656","article-title":"Featurecounts: An Efficient General Purpose Program for Assigning Sequence Reads to Genomic Features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","article-title":"A Scaling Normalization Method for Differential Expression Analysis of RNA-Seq Data","volume":"11","author":"Robinson","year":"2010","journal-title":"Genome Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp616","article-title":"Edger: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Society: Ser B (Methodological)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"R14","DOI":"10.1186\/gb-2010-11-2-r14","article-title":"Gene Ontology Analysis for RNA-Seq: Accounting for Selection Bias","volume":"11","author":"Young","year":"2010","journal-title":"Genome Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"Clusterprofiler: An R Package for Comparing Biological Themes Among Gene Clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102","article-title":"Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlz125","article-title":"Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma","volume":"79","author":"Bodor","year":"2020","journal-title":"J Neuropathol Exp Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12405","article-title":"Frequency of MYD88 and CD79B Mutations, and MGMT Methylation in Primary Central Nervous System Diffuse Large B-Cell Lymphoma","volume":"37","author":"Zheng","year":"2017","journal-title":"Neuropathol Off J Japanese Soc Neuropathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12259","article-title":"Recurrent Mutations of CD79B and MYD88 Are the Hallmark of Primary Central Nervous System Lymphomas","volume":"42","author":"Nakamura","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1536-2","article-title":"Genomic Characterization of Primary Central Nervous System Lymphoma","volume":"131","author":"Fukumura","year":"2016","journal-title":"Acta Neuropathologica"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.264","article-title":"The Mutational Pattern of Primary Lymphoma of the Central Nervous System Determined by Whole-Exome Sequencing","volume":"29","author":"Vater","year":"2015","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy Plus Rituximab Compared With CHOP Alone in Elderly Patients With Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-Like Chemotherapy Plus Rituximab Versus CHOP-Like Chemotherapy Alone in Young Patients With Good-Prognosis Diffuse Large-B-Cell Lymphoma: A Randomised Controlled Trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-010-0269-7","article-title":"Survival Among Patients With Primary Central Nervous System Lymphoma, 1973-2004","volume":"101","author":"Norden","year":"2011","journal-title":"J Neuro-Oncol"},{"key":"B31","article-title":"Primary Brain Tumors in Adults: Diagnosis and Treatment","volume":"93","author":"Perkins","year":"2016","journal-title":"Am Fam Physician"},{"key":"B32","article-title":"The Impact of BCL-2\/MYC Protein Expression and Gene Abnormality on Primary Central Nervous System Diffuse Large B-Cell Lymphoma","volume":"12","author":"Yin","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16451","article-title":"Induction Therapy With the MATRix Regimen in Patients With Newly Diagnosed Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System - an International Study of Feasibility and Efficacy in Routine Clinical Practice","volume":"189","author":"Schorb","year":"2020","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy With Methotrexate, Cytarabine, Thiotepa, and Rituximab (MATRix Regimen) in Patients With Primary CNS Lymphoma: Results of the First Randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) Phase 2 Trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas","volume":"21","author":"Braggio","year":"2015","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2018.08.012","article-title":"Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes","volume":"20","author":"Zhou","year":"2018","journal-title":"Neoplasia (New York NY)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.32598\/bcn.11.4.2542.1","article-title":"Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","volume":"11","author":"Monabati","year":"2020","journal-title":"Basic Clin Neurosci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2019.12.006","article-title":"Rapid Progressive Lung Cancers Harbouring Multiple Clonal Driver Mutations With Big Bang Evolution Model","volume":"241","author":"Kunimasa","year":"2020","journal-title":"Cancer Genet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5386","DOI":"10.1038\/s41467-019-13001-y","article-title":"Invariant Patterns of Clonal Succession Determine Specific Clinical Features of Myelodysplastic Syndromes","volume":"10","author":"Nagata","year":"2019","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2019.08.004","article-title":"Rectal Cancer Sub-Clones Respond Differentially to Neoadjuvant Therapy","volume":"21","author":"Frydrych","year":"2019","journal-title":"Neoplasia (New York NY)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.0c13852","article-title":"A Sequentially Responsive Nanosystem Breaches Cascaded Bio-Barriers and Suppresses P-Glycoprotein Function for Reversing Cancer Drug Resistance","volume":"12","author":"Liu","year":"2020","journal-title":"ACS Appl Mater Interfaces"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005064","article-title":"Effects of Germline DHFR and FPGS Variants on Methotrexate Metabolism and Relapse of Leukemia","volume":"136","author":"Tulstrup","year":"2020","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17319","article-title":"Exome Sequencing Identifies SLIT2 Variants in Primary CNS Lymphoma","volume":"193","author":"Kaulen","year":"2021","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.824632\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T07:59:29Z","timestamp":1644393569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.824632\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":45,"alternative-id":["10.3389\/fonc.2022.824632"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.824632","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"article-number":"824632"}}